A novel microfluidic anti-factor Xa assay device for monitoring anticoagulant therapy at the point-of-care

Leanne F. Harris; Paul Rainey; Vanessa Castro-López; James S. O'Donnell; Anthony J. Killard

doi:10.1117/12.2016872

28 May 2013 A novel microfluidic anti-factor Xa assay device for monitoring anticoagulant therapy at the point-of-care

Leanne F. Harris, Paul Rainey, Vanessa Castro-López, James S. O'Donnell, Anthony J. Killard

Proceedings Volume 8765, Bio-MEMS and Medical Microdevices; 876509 (2013) https://doi.org/10.1117/12.2016872
Event: SPIE Microtechnologies, 2013, Grenoble, France

Abstract

Millions of patients worldwide are receiving anticoagulant therapy to treat hypercoagulable diseases. While standard testing is still performed in the central laboratory, point-of-care (POC) diagnostics are being developed due to the increasing number of patients requiring long-term anticoagulation and with a need for more personalized and targeted therapy. Many POC devices on the market focus on clot measurement, a technique which is limited in terms of variability, highlighting the need for more reliable assays of anticoagulant status. The anti-Xa assay, a factor specific optical assay, was developed to measure the extent to which exogenous factor Xa (FXa) is inhibited by heparinantithrombin complexes. We have developed a novel microfluidic device and assay for monitoring the effect of heparin anticoagulant therapy at the point-of-care. The assay which was also developed in our institute is based on the anti-Xa assay principle but uses fluorescence as the method of detection. Our device is a disposable laminate microfluidic strip, fabricated from the cyclic polyolefin (COP), Zeonor®, which is extremely suitable for application to fluorescent device platforms. We present data on the execution of the anti-Xa assay in this microfluidic format, demonstrating that the assay can be used to measure heparin in human plasma samples from 0 to 0.8 U/ml, with average assay reproducibility of 8% and a rapid result obtained within 60 seconds. Results indicate that with further development, the fluorogenic anti-Xa assay and device could become a successful method for monitoring anticoagulant therapy.

Citation Download Citation

Leanne F. Harris, Paul Rainey, Vanessa Castro-López, James S. O'Donnell, and Anthony J. Killard "A novel microfluidic anti-factor Xa assay device for monitoring anticoagulant therapy at the point-of-care", Proc. SPIE 8765, Bio-MEMS and Medical Microdevices, 876509 (28 May 2013); https://doi.org/10.1117/12.2016872

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available